We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Vaccination of Patients With Renal Cell Cancer With Dendritic Cell Tumor Fusions and GM-CSF

This study is ongoing, but not recruiting participants.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00458536
First Posted: April 11, 2007
Last Update Posted: July 28, 2017
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Collaborator:
National Cancer Institute (NCI)
Information provided by (Responsible Party):
David Avigan, MD, Beth Israel Deaconess Medical Center
Results First Submitted: January 20, 2016  
Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment;   Masking: None (Open Label);   Primary Purpose: Treatment
Condition: Renal Cancer
Interventions: Biological: Dendritic Cell Tumor Fusion Vaccine
Drug: Granulocyte Macrophage Colony Stimulating Factor (GM-CSF)

  Participant Flow
  Hide Participant Flow

Recruitment Details
Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
No text entered.

Pre-Assignment Details
Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
No text entered.

Reporting Groups
  Description
Patients Treated With Vaccine Patients with renal cell carcinoma following debulking nephrectomy who receive at least 2 doses of DC/renal fusion vaccine.

Participant Flow:   Overall Study
    Patients Treated With Vaccine
STARTED   38 
COMPLETED   19 
NOT COMPLETED   19 
Disease progression prior to treatment                7 
Unable to make vaccine                3 
No measurable disease after surgery                2 
Did not have renal cell carcinoma                2 
Patient did not have surgery                1 
Ineligible due to toxicity                1 
Withdrawal by Subject                1 
Progressive disease during treatment                2 



  Baseline Characteristics
  Hide Baseline Characteristics

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
No text entered.

Reporting Groups
  Description
Patients Treated With Vaccine Patients with renal cell carcinoma following debulking nephrectomy who receive at least 2 doses of DC/renal fusion vaccine.

Baseline Measures
   Patients Treated With Vaccine 
Overall Participants Analyzed 
[Units: Participants]
 19 
Age, Customized 
[Units: Years]
Median (Full Range)
 56 
 (43 to 79) 
Sex: Female, Male 
[Units: Participants]
Count of Participants
 
Female      6  31.6% 
Male      13  68.4% 
Region of Enrollment 
[Units: Participants]
 
United States   19 


  Outcome Measures

1.  Primary:   Number of Participants With Adverse Events Associated With Vaccination With Mature DC/Tumor Fusion and GM-CSF   [ Time Frame: 5 years ]

2.  Secondary:   To Determine if Cellular and Humoral Immunity is Induced by Serial Vaccination With DC/Tumor Fusion Cells and GM-CSF   [ Time Frame: 5 years ]
Results not yet reported.   Anticipated Reporting Date:   No text entered.  

3.  Secondary:   to Correlate Immunologic Response Following Vaccination.   [ Time Frame: 5 years ]
Results not yet reported.   Anticipated Reporting Date:   No text entered.  


  Serious Adverse Events


  Other Adverse Events


  Limitations and Caveats
  Hide Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
No text entered.


  More Information
  Hide More Information

Certain Agreements:  
Principal Investigators are NOT employed by the organization sponsoring the study.
There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.


Results Point of Contact:  
Name/Title: David Avigan, MD
Organization: Beth Israel Deaconess Medical Center
phone: 617-667-9920
e-mail: davigan@bidmc.harvard.edu



Responsible Party: David Avigan, MD, Beth Israel Deaconess Medical Center
ClinicalTrials.gov Identifier: NCT00458536     History of Changes
Other Study ID Numbers: 04-117
First Submitted: April 10, 2007
First Posted: April 11, 2007
Results First Submitted: January 20, 2016
Results First Posted: February 17, 2016
Last Update Posted: July 28, 2017